RecruitingPhase 1NCT07004244

Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies

Safety and Efficacy of KRAS Vaccine in the Treatment of KRAS-mutant Malignancies

Sponsor

Sichuan University

Enrollment

20 participants

Start Date

Jun 5, 2025

Study Type

INTERVENTIONAL

Conditions

Malignant Tumors

Summary

The goal of this study is to evaluate the safety and efficacy of mRNA vaccine for the KRAS mutation malignant tumors.

Eligibility

Min Age: 18 Years

Inclusion Criteria13

Male or female participants ≥18 years of age.
Participants with solid tumors confirmed to carry KRAS mutations.
At least one measurable lesion according to RECIST 1.1 criteria.
ECOG physical condition score: 0-1 point.
Adequate organ and bone marrow function.
Ability to understand and voluntarily provide written informed consent before trial participation.
Cohort 1:
Failure of prior standard therapy, intolerance to standard therapy, ineligibility for standard therapy, or absence of a standard treatment regimen.
Life expectancy ≥3 months.
Cohort 2:
Newly diagnosed, treatment-naïve lung adenocarcinoma confirmed by pathology (histology/cytology).
Resectable disease classified as stage IB-IIIA per AJCC 9th edition criteria.
KRAS G12C/G12D/G12V/G13D mutation-positive by genomic testing.

Exclusion Criteria18

Patients with a history of other malignancies.
Presence of primary central nervous system (CNS) tumors, active CNS metastatic tumors, or carcinomatous meningitis, either historically or identified during screening.
Uncontrolled moderate to massive serous cavity effusion.
Confirmed presence of other classic gene variants.
Known cardiac clinical symptoms or diseases that are poorly controlled.
Unstable thrombotic events (e.g., deep vein thrombosis, arterial thrombosis, pulmonary embolism) requiring therapeutic intervention within 6 months prior to screening.
Any active autoimmune disease or a history of autoimmune disease.
Uncontrolled clinical disorders, psychiatric illnesses, or other significant diseases as assessed by the investigator that may interfere with informed consent, compromise interpretation of trial results, pose risks to participants, or otherwise hinder the achievement of trial objectives.
History of interstitial pneumonia or suspected interstitial pneumonia; or pulmonary abnormalities that may interfere with the detection or management of suspected drug-related pulmonary toxicity during the trial.
Hypersensitivity to the investigational drug (including any excipients).
Patients who received anti-tumor therapy within 4 weeks prior to the first dose, or those with unresolved adverse reactions (except alopecia) from prior anti-tumor therapy (NCI CTCAE > grade 1).
Systemic use of corticosteroids (>10 mg/day prednisone or equivalent) or other immunosuppressants within 14 days prior to the first dose.
Participants who received drugs of the same class within 6 months prior to the first dose.
Prior organ transplantation or allogeneic hematopoietic stem cell transplantation.
Active hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), or syphilis infection.
Active tuberculosis (TB) or a history of active TB; or severe acute/chronic infections requiring systemic treatment.
Pregnant or lactating women.
Any other factors deemed by the investigator to render the participant unsuitable for trial participation.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALKRAS-mutated mRNA vaccine

Cohort 1:From the initial dose, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose. Cohort 2:KRAS-mutated mRNA vaccine+ Toripalimab + pemetrexed + carboplatin as neo-adjuvant treatment followed by surgery

BIOLOGICALTORIPALIMAB

intravenous injection

DRUGPemetrexed+carboplatin

intravenous injection